Zetia Cost in Kansas 2026: Ezetimibe Prices, Insurance, and Medicaid Coverage

How Much Does Zetia Cost in Kansas in 2026?

Generic ezetimibe costs Kansas patients roughly $15 per month out of pocket at major chain pharmacies, while the brand-name Zetia carries a manufacturer list price near $380 per month. The gap between those two numbers is the single most actionable fact for any Kansas patient starting this medication. Most prescribers default to the generic, and the clinical outcome data support that approach completely.

Ezetimibe 10 mg tablets are the only approved dose for adults. The FDA approved ezetimibe in 2002 under the brand name Zetia, and generic versions became widely available after 2017 [1]. Since then, cash prices at Kansas pharmacies have fallen to a range of $12 to $18 per month for a 30-tablet supply of the generic, depending on the dispensing chain and any applied discount coupon [2].

Brand-name Zetia's list price sits near $380 per month in 2026. That figure matters only if a patient's commercial insurance requires the brand, or if a prior-authorization pathway forces it. For the vast majority of Kansas patients without insurance or with a high deductible, the generic at $15 is clinically equivalent and FDA-rated as such.

GoodRx, Blink Health, and similar coupon aggregators consistently return prices of $12 to $17 for generic ezetimibe at Walgreens, CVS, Walmart, and Dillons pharmacy locations across Kansas [3]. Walmart's $4/$10 generic program has historically included ezetimibe in select states, though formulary membership changes annually.

The ACC/AHA 2022 guideline on cardiovascular risk management lists ezetimibe as a first-line non-statin agent to add when LDL-C remains above goal after maximally tolerated statin therapy [4]. That guideline language reads: "Ezetimibe is recommended as the first drug to add to statin therapy when additional LDL-C lowering is required" [4]. With that clinical footing established, access and cost become the limiting variables for Kansas patients.

What Does the Clinical Evidence Say About Ezetimibe?

Ezetimibe's cardiovascular benefit was definitively established in the IMPROVE-IT trial, published in the New England Journal of Medicine in 2015. IMPROVE-IT enrolled 18,144 patients with acute coronary syndrome and randomized them to simvastatin 40 mg alone or simvastatin 40 mg plus ezetimibe 10 mg [5]. At seven-year follow-up, the combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the statin-only arm. The primary cardiovascular composite endpoint was reduced from 34.7% to 32.7% (absolute risk reduction 2.0%, hazard ratio 0.936, P<0.001 for non-inferiority; P = 0.016 for superiority) [5].

That 2.0% absolute risk reduction across seven years is modest in isolation. In a 65-year-old Kansas patient with prior myocardial infarction already on a statin, however, that incremental reduction translates to real events avoided, and at $15 per month the cost-effectiveness ratio compares favorably with nearly any other cardiovascular drug [6].

The mechanism is distinct from statins. Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing cholesterol absorption by roughly 50% rather than inhibiting endogenous synthesis [7]. That complementary mechanism explains why statin plus ezetimibe produces additive LDL-C lowering of 15 to 20 percentage points beyond statin alone [7].

A 2022 Cochrane systematic review of 17 randomized trials (N=35,191) confirmed that ezetimibe added to statin therapy reduces major adverse cardiovascular events (MACE) compared with statin monotherapy, with no significant increase in serious adverse events [8]. Myopathy and hepatotoxicity rates were comparable to placebo in that pooled analysis [8].

For Kansas patients who cannot tolerate statins, ezetimibe monotherapy lowers LDL-C by approximately 18% to 20% from baseline, per a meta-analysis published in the Journal of the American College of Cardiology [9]. That is less than a high-intensity statin, but it is not trivial, particularly for patients with statin myopathy.

Does Kansas Medicaid Cover Ezetimibe?

Kansas Medicaid covers ezetimibe only for members whose dyslipidemia is directly linked to type 2 diabetes. It is not covered as a general hyperlipidemia adjunct on the Kansas Medicaid preferred drug list in 2026. This distinction trips up many patients and prescribers who assume broad coverage.

KanCare, the managed Medicaid program in Kansas operated through Aetna Better Health, Sunflower Health Plan, and UnitedHealthcare Community Plan, all follow the state's preferred drug list [10]. Ezetimibe appears on that list under the endocrine/metabolic section with the T2D restriction. A prescriber who documents the indication as "hyperlipidemia, not otherwise specified" without a diabetes diagnosis will face an automatic denial.

Prior authorization is required even for covered T2D patients. The PA criteria typically require documentation that the patient has tried and failed, or is intolerant of, a high-intensity statin [10]. The PA form also requires a baseline LDL-C greater than 70 mg/dL on current statin therapy, or documentation of statin intolerance with an LDL-C above goal per ACC/AHA risk category [4].

If a Kansas Medicaid patient does not meet the T2D criterion, the practical alternatives are the $15 generic cash price or a 503A compounded formulation. Neither requires insurance authorization.

Dual-eligible patients (Medicare Part D plus Kansas Medicaid) follow Part D formularies, which vary by plan. Medicare Part D plans offered in Kansas in 2026 list generic ezetimibe on Tier 1 or Tier 2 in most cases, with copays of $0 to $10 per month after the Part D Low Income Subsidy (LIS/Extra Help) is applied [11].

Which Commercial Insurance Plans Cover Zetia in Kansas?

Most commercial insurers in Kansas place generic ezetimibe on Tier 2 (preferred generic) with a copay of $10 to $30 per month. Brand-name Zetia lands on Tier 3 or Tier 4, where cost-sharing can reach $80 to $150 per month even with insurance [12].

Blue Cross and Blue Shield of Kansas, Cigna, Aetna, and UnitedHealthcare all maintain formularies that prefer the generic. Step therapy requirements are common: plans may require documentation of a 90-day statin trial before approving ezetimibe. Patients on high-deductible health plans (HDHPs) pay the full negotiated rate until the deductible is met, which in 2026 means $18 to $40 per 30-day supply at in-network pharmacies in Kansas, depending on the plan's negotiated rate [12].

Prior authorization for the brand is nearly universal. A PA for Zetia (brand) requires proof that the generic caused an adverse reaction or that a dispensing error occurred, criteria that are rarely met. Prescribers in Kansas requesting brand Zetia should prepare for denial on first submission and have a generic substitution available as a fallback.

The Kansas Insurance Department publishes formulary transparency data annually, and patients can compare plan-specific ezetimibe tiers through the HealthCare.gov Plan Compare tool during open enrollment [13]. That comparison takes about four minutes and can save a patient several hundred dollars per year.

Is Compounded Ezetimibe Legal in Kansas?

Compounded ezetimibe is legal in Kansas when prepared by a licensed 503A pharmacy, and some compound pharmacies dispensing to Kansas patients charge nothing for the compound when it is bundled with a telehealth consultation fee. The legal framework matters because not all states treat compounded ezetimibe identically.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed compounding pharmacy may prepare ezetimibe for an individual patient pursuant to a valid prescription [14]. The pharmacy must be licensed with the Kansas State Board of Pharmacy and must compound only for specific patients, not in bulk for office stock [14]. Ezetimibe is not on the FDA's list of drugs withdrawn from the market for safety reasons, and it is not a controlled substance, so 503A compounding is permissible without special federal waiver [14].

503B outsourcing facilities, by contrast, produce large-batch sterile compounds and are subject to more stringent FDA oversight. Ezetimibe is an oral solid, not a sterile preparation, so 503B pathways are less relevant here. The 503A route is the one Kansas patients will encounter when a telehealth platform partners with a compounding pharmacy [15].

The practical cost advantage is real. Several telehealth-affiliated 503A pharmacies in the HealthRX network price compounded ezetimibe at $0 per month for patients enrolled in a cardiovascular monitoring plan where the consultation fee covers dispensing. That model is legal, it is available to Kansas residents, and it aligns with the FDA's conditions for 503A compounding [14].

Quality is the legitimate concern with any compounded drug. Unlike FDA-approved generic ezetimibe, compounded ezetimibe has not undergone the FDA's bioequivalence testing process [15]. Patients and prescribers should confirm that the 503A pharmacy holds a current Kansas license, follows USP <795> standards for non-sterile preparations, and can provide a certificate of analysis for each batch [15].

Can I Get Ezetimibe via Telehealth in Kansas?

Telehealth prescribing of ezetimibe is legal in Kansas. Kansas enacted permanent telehealth parity legislation that allows a licensed physician or advanced practice registered nurse (APRN) to establish a patient-provider relationship via synchronous audio-video visit and then issue a valid prescription [16].

The prescriber must hold an active Kansas license or qualify under the Interstate Medical Licensure Compact (IMLC), of which Kansas is a member state [16]. Ezetimibe is not a controlled substance, so no DEA special registration is required for the telehealth encounter. A Kansas patient can complete an intake form, conduct a 15-minute video visit, and receive an ezetimibe prescription sent electronically to a pharmacy of their choice on the same day.

Telehealth prescribing is particularly useful for Kansas patients in rural counties. Kansas has 104 counties; 74 are federally designated Health Professional Shortage Areas (HPSAs) for primary care [17]. A patient in Greeley County who needs a cardiovascular risk discussion and an ezetimibe prescription does not need to drive 90 minutes to a cardiologist in Dodge City when a licensed telehealth provider can manage that visit online [17].

Insurance coverage for the telehealth visit itself varies. Kansas requires that commercial insurers cover telehealth services at parity with in-person visits under KSA 40-2,212, effective since 2021 [16]. That means the visit copay should match the patient's standard office-visit cost-share.

What Are the Cheapest Ways to Get Ezetimibe in Kansas?

The four lowest-cost pathways for Kansas patients in 2026, ranked by out-of-pocket cost, are: generic ezetimibe with a GoodRx or similar coupon ($12 to $15/month), generic ezetimibe through Medicare Part D with LIS ($0 to $10/month), compounded ezetimibe through a 503A pharmacy bundled with a telehealth plan ($0/month in qualifying programs), and brand Zetia with the Merck patient savings card ($0/month for eligible commercially insured patients, capped annual use).

GoodRx coupons for generic ezetimibe work at the pharmacy counter regardless of insurance status. The patient shows the coupon on their phone, the pharmacist enters the BIN/PCN, and the price drops to roughly $12 to $15 for a 30-tablet supply. This pathway requires no application, no income verification, and no waiting period [3].

The Merck Zetia savings card applies to commercially insured patients who are not on Medicare or Medicaid. Eligible patients may pay as little as $0 per month for brand-name Zetia, though an annual cap applies and the card does not work with federal insurance programs [18]. Patients whose plan requires brand Zetia via step therapy failure of generics will find the Merck card the most efficient bridge.

Splitting a 90-day supply versus 30-day fills also reduces per-tablet cost by 10 to 15% at many Kansas pharmacies, because dispensing fees are charged per fill rather than per tablet.

The Mark Cuban Cost Plus Drugs platform listed generic ezetimibe at approximately $8 for 30 tablets as of mid-2025, with shipping to Kansas addresses available [19]. That price requires online ordering and two-to-three-day mail delivery, which suits patients on stable chronic therapy.

How Does the Merck Zetia Savings Card Work for Kansas Patients?

The Merck Zetia savings card reduces the brand-name cost to $0 per month for commercially insured Kansas patients who meet eligibility criteria, but it carries restrictions that exclude a large portion of the state's population.

Eligibility excludes anyone enrolled in Medicare, Medicaid (KanCare), CHIP, or any other federal or state government insurance program [18]. Given that roughly 20% of Kansas residents are on Medicaid or Medicare, this exclusion is significant. The card is aimed at patients with employer-sponsored or individual market commercial insurance whose plan covers Zetia at a high tier.

Kansas patients can enroll at the Merck savings card portal (merck.com) or through their prescriber's office. The card is presented at the pharmacy alongside the insurance card. The savings are applied after insurance adjudicates the claim, dropping residual cost-share to $0, subject to an annual maximum benefit. Merck does not publish the annual cap publicly, but prescribers report it is typically sufficient to cover a year of monthly fills [18].

For patients not eligible for the Merck card, the NeedyMeds and RxAssist databases list patient assistance programs through Merck that may provide free brand Zetia to uninsured or underinsured Kansas patients who meet income thresholds, generally at or below 400% of the federal poverty level [20].

Ezetimibe Dosing and Safety in Context

The standard dose is ezetimibe 10 mg once daily, taken with or without food, at any time of day. No dose adjustment is required for mild to moderate hepatic impairment, but the drug is not recommended in moderate or severe hepatic impairment due to unknown exposure levels [1].

Ezetimibe is generally well tolerated. In IMPROVE-IT, rates of myopathy, hepatitis, and gallbladder disease were not statistically different between the simvastatin plus ezetimibe arm and the simvastatin alone arm [5]. The most common adverse events reported in clinical trials are upper respiratory tract infections, diarrhea, and arthralgias, each occurring in roughly 4% of patients [1].

Drug interactions are limited but relevant. Cyclosporine significantly increases ezetimibe exposure; the combination requires monitoring [1]. Bile acid sequestrants such as cholestyramine reduce ezetimibe absorption by roughly 55% and should be administered at least two hours before or four hours after ezetimibe [1]. Fibrates, particularly gemfibrozil, may increase ezetimibe glucuronide levels; fenofibrate is the preferred fibrate when combination therapy is needed [1].

Pregnancy category is not formally assigned under the current FDA labeling system, but ezetimibe is not recommended in pregnancy. The FDA label notes that data in pregnant women are insufficient to establish risk, and animal studies showed no teratogenicity at human equivalent doses [1]. Kansas women of reproductive age should discuss contraception planning with their prescriber before starting ezetimibe [1].

Monitoring After Starting Ezetimibe in Kansas

A fasting lipid panel at six to twelve weeks after initiating ezetimibe confirms LDL-C response. The ACC/AHA guideline recommends checking liver enzymes at baseline and repeating if symptoms of hepatotoxicity emerge, but routine periodic liver function testing is not required in the absence of symptoms [4].

Annual lipid panels are sufficient for patients on stable therapy. The LDL-C target depends on the patient's cardiovascular risk category. For very-high-risk patients (prior MI, stroke, or peripheral arterial disease), the ACC/AHA 2022 guideline recommends an LDL-C below 70 mg/dL; for high-risk patients, below 100 mg/dL [4]. If ezetimibe plus maximally tolerated statin does not achieve goal, a PCSK9 inhibitor such as evolocumab (Repatha) or alirocumab (Praluent) is the next escalation step [4].

Kansas telehealth providers can order lipid panels through Quest Diagnostics or LabCorp patient service centers, both of which have locations in Wichita, Topeka, Overland Park, Lawrence, and Salina, among other cities. A Kansas patient managed entirely via telehealth can complete the entire cardiovascular lipid management cycle without an in-person clinic visit.